To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma

NCT07454187 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Multiple Myeloma

Interventions

DRUG: SG2918

Sponsor

Hangzhou Sumgen Biotech Co., Ltd.